NK Cells Plus Vactosertib
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
What's the purpose of the trial?
There is one center participating in this trial. Enter a location below to view the distance.
Learn more about the experimental treatments being evaluated in this clinical trial.
- Vactosertib is a small molecule TGF-β type I receptor kinase inhibitor.
- Fludarabine is a chemotherapy agent used in the treatment of cancer.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Natural Killer (NK) Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
- Interleukin-2 is an immunotherapy drug used to treat several different indications. It works to help certain parts of your immune system to increase production of immune cells.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!